Clinical Trial Applications - Approved: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Approved | |
|---|---|---|---|---|---|
491. |
ECCT/18/06/01 | Safety, Acceptability, and Feasibility of enterade® (SAFE) Safety, Acceptability, and Feasibility of enterade® in children at risk for environmental enteric dysfunction in Kakamega County, Kenya |
Principal Investigator(s) 1. Michael Benjamin Arndt 2. James Mukabi Site(s) in Kenya Kakamega County General Hospital (CGH) |
02-10-2018 |
View |
492. |
ECCT/25/12/01 | Accetability testing Study Assessing the acceptability of enhanced multiple micronutrient supplements among pregnant women in Bungoma County |
Principal Investigator(s) 1. Zipporah Nekesa Bukania Site(s) in Kenya Tongaren Subcounty, Bungoma County |
14-07-2026 |
View |
493. |
ECCT/18/07/01 | CCNO17 Male contraception study. Clinical Evaluation of Daily Application of Nestorone® (NES) and Testosterone (T) Combination Gel for Male Contraception. |
Principal Investigator(s) 1. Dr John Kinuthia Site(s) in Kenya Couples counselling Center |
19-11-2018 |
View |
494. |
ECCT/23/10/08 | VALUE Placebo Film Study Trial to Assess Acceptability and Safety of Two Placebo Prototype Vaginal Films (MATRIX-002) |
Principal Investigator(s) 1. Nelly Rwamba Mugo Site(s) in Kenya KEMRI-CCR PHRD Thika |
17-01-2024 |
View |
495. |
ECCT/24/02/09 | pionERA This is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of giredestrant compared with fulvestrant, both in combination with the investigator's choice of a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib), in participants with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer who have developed resistance to adjuvant endocrine therapy. |
Principal Investigator(s) 1. Dr Sitna Ali Site(s) in Kenya University of Nairobi -Institute of Tropical and Infectious Diseases |
04-08-2024 |
View |
496. |
ECCT/20/12/02 | MERS-201 Study to Evaluate the Safety, Tolerability and Immunogenicity of INO-4700 for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Healthy Volunteers |
Principal Investigator(s) 1. Bernhards Ogutu 2. Josphat Kosgei Site(s) in Kenya 1. Ahero Clinical Trials Unit (Kisumu county) 2. Kenya Medical Research Institute/Walter Reed Project (KEMRI/WRP) (Kericho county) |
15-07-2021 |
View |
497. |
ECCT/24/09/01 | L9LS-PD Single-use antimalarial monoclonal antibodies for post-discharge malaria prevention in children with severe anaemia or severe malaria in Kenya: A multi-centre, parallel-group, two-arm randomised placebo-controlled non-inferiority trial (L9LS-pd) |
Principal Investigator(s) 1. Mary Iwaret Otiti Site(s) in Kenya 1. Homa Bay County Teaching and Referral Hospital (Homa Bay county) 2. Siaya County Referral Hospital (Siaya county) |
16-03-2025 |
View |
498. |
ECCT/24/04/03 | SMAART-MAP trial Severe Malaria A Research and Trials consortium - Multisite Adaptive Platform trial |
Principal Investigator(s) 1. Prof Kathryn Maitland Maitland Site(s) in Kenya Kilifi County Hospital |
29-08-2024 |
View |
499. |
ECCT/20/11/02 | IAVI C100 Safety and Pharmacokinetics of the Combination Broadly Neutralizing Antibodies, 3BNC117-LS-J and 10-1074-LS-J, in Healthy American and African Adults (IAVI C100) |
Principal Investigator(s) 1. Nelly Mugo Site(s) in Kenya 1. Partners in Health Research and Development (PHRD) – CCR-KEMRI (Kiambu county) 2. Kenya AIDS Vaccine Initiative- Institute of Clinical Research (KAVI-ICR) (Nairobi City county) |
03-03-2021 |
View |
500. |
ECCT/24/08/02 | S4V02 Safety and immunogenicity of a second generation Shigella bioconjugate vaccine: a phase II randomized, controlled, and blinded study in 9-month-old infants |
Principal Investigator(s) 1. Richard Omore Site(s) in Kenya Siaya County Referral Hospital |
07-01-2025 |
View |